Joannes F M Jacobs

List of Publications by Year
in descending order

76	3,889	147801	123424
papers	citations	31 h-index	61 g-index

76	76	76	6313
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	Method comparison of three serum free light chain assays on the Roche Cobas 6000 c501 chemistry analyzer. Clinical Chemistry and Laboratory Medicine, 2022, 60, 379-385.	2.3	2
2	Allogeneic and autologous serum eye drops: a pilot doubleâ€blind randomized crossover trial. Acta Ophthalmologica, 2021, 99, 837-842.	1.1	17
3	Clonotypic Features of Rearranged Immunoglobulin Genes Yield Personalized Biomarkers for Minimal Residual Disease Monitoring in Multiple Myeloma. Clinical Chemistry, 2021, 67, 867-875.	3.2	12
4	FLC polymerization: Another hurdle towards standardization of FLC measurements. Clinica Chimica Acta, 2021, 515, 42-43.	1.1	4
5	Monitoring the M-protein of multiple myeloma patients treated with a combination of monoclonal antibodies: the laboratory solution to eliminate interference. Clinical Chemistry and Laboratory Medicine, 2021, 59, 1963-1971.	2.3	14
6	External quality assessment of M-protein diagnostics: a realistic impression of the accuracy and precision of M-protein quantification. Clinical Chemistry and Laboratory Medicine, 2021, 59, 1063-1068.	2.3	5
7	Multiple Myeloma Minimal Residual Disease Detection: Targeted Mass Spectrometry in Blood vs Next-Generation Sequencing in Bone Marrow. Clinical Chemistry, 2021, 67, 1689-1698.	3.2	24
8	Integrating Serum Protein Electrophoresis with Mass Spectrometry, A New Workflow for M-Protein Detection and Quantification. Journal of Proteome Research, 2020, 19, 2845-2853.	3.7	15
9	Cerebrospinal Fluid Penetrance of Daratumumab in Leptomeningeal Multiple Myeloma. HemaSphere, 2020, 4, e413.	2.7	8
10	An international multi-center serum protein electrophoresis accuracy and M-protein isotyping study. Part I: factors impacting limit of quantitation of serum protein electrophoresis. Clinical Chemistry and Laboratory Medicine, 2020, 58, 533-546.	2.3	36
11	An international multi-center serum protein electrophoresis accuracy and M-protein isotyping study. Part II: limit of detection and follow-up of patients with small M-proteins. Clinical Chemistry and Laboratory Medicine, 2020, 58, 547-559.	2.3	32
12	Clone-directed therapy for proliferative glomerulonephritis with monoclonal immunoglobulin depositions: is it always necessary?. Journal of Nephrology, 2020, 33, 611-617.	2.0	8
13	Minimal Residual Disease in Multiple Myeloma: Targeted Mass Spectrometry in Blood Vs Next Generation Sequencing in Bone Marrow. Blood, 2020, 136, 9-9.	1.4	1
14	Plasma therapy leads to an increase in functional IgA and IgM concentration in the blood and saliva of a patient with X-linked agammaglobulinemia. Journal of Translational Medicine, 2019, 17, 174.	4.4	5
15	Broad Bands Observed in Serum Electrophoresis Should Not Be Taken Lightly. Clinical Chemistry, 2019, 65, 618-621.	3.2	2
16	Method comparison of four clinically available assays for serum free light chain analysis. Clinical Chemistry and Laboratory Medicine, 2019, 58, 85-94.	2.3	21
17	Analytical validation of the Hevylite assays for M-protein quantification. Clinical Chemistry and Laboratory Medicine, 2018, 56, 1169-1175.	2.3	7
18	Development of a Targeted Mass-Spectrometry Serum Assay To Quantify M-Protein in the Presence of Therapeutic Monoclonal Antibodies. Journal of Proteome Research, 2018, 17, 1326-1333.	3.7	32

#	Article	IF	Citations
19	Recognition and management of common, rare, and novel serum protein electrophoresis and immunofixation interferences. Clinical Biochemistry, 2018, 51, 72-79.	1.9	28
20	Evaluation of a new free light chain ELISA assay: bringing coherence with electrophoretic methods. Clinical Chemistry and Laboratory Medicine, 2018, 56, 312-322.	2.3	26
21	Reference ranges of the Sebia free light chain ratio in patients with chronic kidney disease. Clinical Chemistry and Laboratory Medicine, 2018, 56, e232-e234.	2.3	13
22	Simultaneous Presence of Non- and Highly Mutated Keyhole Limpet Hemocyanin (KLH)-Specific Plasmablasts Early after Primary KLH Immunization Suggests Cross-Reactive Memory B Cell Activation. Journal of Immunology, 2018, 200, 3981-3992.	0.8	18
23	Standardization and harmonization of autoimmune diagnostics. Clinical Chemistry and Laboratory Medicine, 2018, 56, 1563-1567.	2.3	22
24	Single-cell analysis reveals that stochasticity and paracrine signaling control interferon-alpha production by plasmacytoid dendritic cells. Nature Communications, 2018, 9, 3317.	12.8	116
25	The Role of FcRn in the Pharmacokinetics of Biologics in Patients With Multiple Myeloma. Clinical Pharmacology and Therapeutics, 2017, 102, 903-904.	4.7	9
26	Development of a rapid and quantitative lateral flow assay for the simultaneous measurement of serum Î° and Î» immunoglobulin free light chains (FLC): inception of a new near-patient FLC screening tool. Clinical Chemistry and Laboratory Medicine, 2017, 55, 424-434.	2.3	25
27	Response to: Interference of daratumumab on the serum protein electrophoresis. Clinical Chemistry and Laboratory Medicine, 2017, 55, e29-e30.	2.3	1
28	Monitoring of dynamic changes in Keyhole Limpet Hemocyanin (KLH)-specific B cells in KLH-vaccinated cancer patients. Scientific Reports, 2017, 7, 43486.	3.3	16
29	Changes in peripheral immune cell numbers and functions in octogenarian walkers â€“ an acute exercise study. Immunity and Ageing, 2017, 14, 5.	4.2	15
30	Dendritic Cells as Vaccines: Key Regulators of Tolerance and Immunity. Mediators of Inflammation, 2016, 2016, 1-2.	3.0	4
31	Monitoring multiple myeloma patients treated with daratumumab: teasing out monoclonal antibody interference. Clinical Chemistry and Laboratory Medicine, 2016, 54, 1095-104.	2.3	102
32	Fast, robust and high-resolution glycosylation profiling of intact monoclonal IgG antibodies using nanoLC-chip-QTOF. Clinica Chimica Acta, 2016, 461, 90-97.	1.1	20
33	Interference of daratumumab in monitoring multiple myeloma patients using serum immunofixation electrophoresis can be abrogated using the daratumumab IFE reflex assay (DIRA). Clinical Chemistry and Laboratory Medicine, 2016, 54, 1105-9.	2.3	65
34	Is accuracy of serum free light chain measurement achievable?. Clinical Chemistry and Laboratory Medicine, 2016, 54, 1021-30.	2.3	38
35	Long-lasting multifunctional CD8⁺T cell responses in end-stage melanoma patients can be induced by dendritic cell vaccination. OncoImmunology, 2016, 5, e1067745.	4.6	55
36	Effective Clinical Responses in Metastatic Melanoma Patients after Vaccination with Primary Myeloid Dendritic Cells. Clinical Cancer Research, 2016, 22, 2155-2166.	7.0	211

#	Article	IF	Citations
37	Assessment of serum free light chain levels in healthy adults immediately after marathon running. Clinical Chemistry and Laboratory Medicine, 2016, 54, 459-65.	2.3	6
38	Antiâ€<scp>SSA</scp> antibodies are present in immunoglobulin preparations. Transfusion, 2015, 55, 832-837.	1.6	16
39	Quantitative Measurement of Immunoglobulins and Free Light Chains Using Mass Spectrometry. Analytical Chemistry, 2015, 87, 8268-8274.	6.5	27
40	Humoral and cellular immune responses after influenza vaccination in patients with postcancer fatigue. Human Vaccines and Immunotherapeutics, 2015, 11, 1634-1640.	3.3	2
41	The role of interleukin-1 beta in the pathophysiology of Schnitzlerâ€™s syndrome. Arthritis Research and Therapy, 2015, 17, 187.	3.5	45
42	Intranodal vaccination with mRNA-optimized dendritic cells in metastatic melanoma patients. OncoImmunology, 2015, 4, e1019197.	4.6	55
43	Antigen excess in modern immunoassays: To anticipate on the unexpected. Autoimmunity Reviews, 2015, 14, 160-167.	5.8	51
44	Relatively Restricted Migration of Polyclonal IgG4 May Mimic a Monoclonal Gammopathy in IgG4-Related Disease. American Journal of Clinical Pathology, 2014, 142, 76-81.	0.7	27
45	Early predictive value of multifunctional skin-infiltrating lymphocytes in anticancer immunotherapy. OncoImmunology, 2014, 3, e27219.	4.6	3
46	The impact of exercise on the variation of serum free light chains. Clinical Chemistry and Laboratory Medicine, 2014, 52, e239-42.	2.3	3
47	Reply to Berlanga et al. (DOI 10.1515/cclm-2014-0420). Clinical Chemistry and Laboratory Medicine, 2014, 52, e247-e248.	2.3	0
48	N Latex FLC serum free light-chain assays in patients with renal impairment. Clinical Chemistry and Laboratory Medicine, 2014, 52, 853-9.	2.3	38
49	Severe exacerbation of Crohnâ€™s disease during sunitinib treatment. European Journal of Gastroenterology and Hepatology, 2014, 26, 234-236.	1.6	7
50	Targeting CD4+ T-Helper Cells Improves the Induction of Antitumor Responses in Dendritic Cellâ€“Based Vaccination. Cancer Research, 2013, 73, 19-29.	0.9	131
51	Vaccination with mRNA-Electroporated Dendritic Cells Induces Robust Tumor Antigen-Specific CD4+ and CD8+ T Cells Responses in Stage III and IV Melanoma Patients. Clinical Cancer Research, 2012, 18, 5460-5470.	7.0	86
52	PD-1 Blockade Augments Th1 and Th17 and Suppresses Th2 Responses in Peripheral Blood From Patients With Prostate and Advanced Melanoma Cancer. Journal of Immunotherapy, 2012, 35, 169-178.	2.4	269
53	Regulatory T cells in melanoma: the final hurdle towards effective immunotherapy?. Lancet Oncology, The, 2012, 13, e32-e42.	10.7	219
54	Humoral anti-KLH responses in cancer patients treated with dendritic cell-based immunotherapy are dictated by different vaccination parameters. Cancer Immunology, Immunotherapy, 2012, 61, 2003-2011.	4.2	24

#	Article	IF	Citations
55	Skin-Test Infiltrating Lymphocytes Early Predict Clinical Outcome of Dendritic Cellâ€“Based Vaccination in Metastatic Melanoma. Cancer Research, 2012, 72, 6102-6110.	0.9	50
56	Effect of sample dilution on two free light chain nephelometric assays. Clinica Chimica Acta, 2012, 413, 1708-1709.	1.1	21
57	Anaphylaxis from Passive Transfer of Peanut Allergen in a Blood Product. New England Journal of Medicine, 2011, 364, 1981-1982.	27.0	67
58	Route of Administration Modulates the Induction of Dendritic Cell Vaccineâ€“Induced Antigen-Specific T Cells in Advanced Melanoma Patients. Clinical Cancer Research, 2011, 17, 5725-5735.	7.0	158
59	Sorafenib reduces the percentage of tumour infiltrating regulatory T cells in renal cell carcinoma patients. International Journal of Cancer, 2011, 129, 507-512.	5.1	120
60	Cancer Patients Treated with Sunitinib or Sorafenib Have Sufficient Antibody and Cellular Immune Responses to Warrant Influenza Vaccination. Clinical Cancer Research, 2011, 17, 4541-4549.	7.0	28
61	Frequency of Circulating Tregs with Demethylated FOXP3 Intron 1 in Melanoma Patients Receiving Tumor Vaccines and Potentially Treg-Depleting Agents. Clinical Cancer Research, 2011, 17, 841-848.	7.0	70
62	Early identification of antigen-specific immune responses in vivo by [¹⁸ F]-labeled 3â€²-fluoro-3â€²-deoxy-thymidine ([¹⁸ F]FLT) PET imaging. Proceedings of the National Academy of Sciences of the United States of America, 2011, 108, 18396-18399.	7.1	65
63	Prognostic significance and mechanism of Treg infiltration in human brain tumors. Journal of Neuroimmunology, 2010, 225, 195-199.	2.3	180
64	Dendritic Cell Vaccination in Combination with Anti-CD25 Monoclonal Antibody Treatment: A Phase I/II Study in Metastatic Melanoma Patients. Clinical Cancer Research, 2010, 16, 5067-5078.	7.0	212
65	Overestimation of Serum Îº Free Light Chain Concentration by Immunonephelometry. Clinical Chemistry, 2010, 56, 1188-1190.	3.2	37
66	What is Your Guess? Detecting Only Light Chains, Now What?. Clinical Chemistry, 2010, 56, 1368-1368.	3.2	1
67	Limited Amounts of Dendritic Cells Migrate into the T-Cell Area of Lymph Nodes but Have High Immune Activating Potential in Melanoma Patients. Clinical Cancer Research, 2009, 15, 2531-2540.	7.0	172
68	Regulatory T cells and the PD-L1/PD-1 pathway mediate immune suppression in malignant human brain tumors. Neuro-Oncology, 2009, 11, 394-402.	1.2	203
69	Regulation of MYCNexpression in human neuroblastoma cells. BMC Cancer, 2009, 9, 239.	2.6	28
70	Vaccine-specific local T cell reactivity in immunotherapy-associated vitiligo in melanoma patients. Cancer Immunology, Immunotherapy, 2009, 58, 145-151.	4.2	29
71	Elimination of regulatory T cells is essential for an effective vaccination with tumor lysateâ€pulsed dendritic cells in a murine glioma model. International Journal of Cancer, 2008, 122, 1794-1802.	5.1	78
72	Selective cancer-germline gene expression in pediatric brain tumors. Journal of Neuro-Oncology, 2008, 88, 273-280.	2.9	24

#	Article	IF	Citations
73	Maturation of monocyte-derived dendritic cells with Toll-like receptor 3 and 7/8 ligands combined with prostaglandin E2 results in high interleukin-12 production and cell migration. Cancer Immunology, Immunotherapy, 2008, 57, 1589-1597.	4.2	141
74	Tollâ€like receptor signalling on Tregs: to suppress or not to suppress?. Immunology, 2008, 124, 445-452.	4.4	87
75	Cancer-germline gene expression in pediatric solid tumors using quantitative real-time PCR. International Journal of Cancer, 2007, 120, 67-74.	5.1	70
76	Phenotypic and functional characterization of mature dendritic cells from pediatric cancer patients. Pediatric Blood and Cancer, 2007, 49, 924-927.	1.5	10